Yucai Wang, MD, PhD, discusses the rationale, methods, and design of a study evaluating the efficacy of pembrolizumab when given as both a monotherapy and in combination with B-cell receptor inhibitors for Richter transformation of CLL.
Yucai Wang, MD, PhD
Advertisement
Yucai Wang, MD, PhD, is a hematologist specializing in lymphoma and chronic lymphocytic leukemia at Mayo Clinic.
Articles by Yucai Wang, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
